文献速递神经肿瘤

标准辅助化疗期间多次血脑屏障破坏治疗胶质母细胞瘤的安全性与可行性

Safety and feasibility of multiple blood-brain barrier disruptions for the treatment of glioblastoma in patients undergoing standard adjuvant chemotherapy.
PubMed 文献 · J Neurosurg · 2020-01-03

这项前瞻性、单中心、单臂研究评估了在标准辅助替莫唑胺化疗期间,使用磁共振引导聚焦超声(MRgFUS)对胶质母细胞瘤患者反复破坏血脑屏障(BBBD)的安全性与可行性。6例患者共接受145次BBBD,T1加权MRI在131次(90.3%)观察到钆增强点,T2*加权/GRE MRI在93次(64.1%)观察到类似斑点,两序列结合在134个靶点(92.4%)观察到BBBD,随访MRI斑点消失,6个周期内无BBBD相关影像学改变和临床不良事件。

要点

  • 6例胶质母细胞瘤患者在标准辅助替莫唑胺化疗期间接受145次MRgFUS血脑屏障破坏。
  • T1加权MRI在131次(90.3%)观察到钆增强点,T2*加权/GRE MRI在93次(64.1%)观察到类似斑点。
  • 两序列结合在134个靶点(92.4%)观察到BBBD,随访MRI斑点消失,6个周期内无BBBD相关影像学改变和临床不良事件。

核心结论

  • 本研究首次在恶性脑肿瘤标准化疗方案下对相同靶点重复进行MRgFUS,BBBD操作精确、可重复且安全。
  • 虽然需要更长的随访期,但本研究为因血脑屏障而此前无法使用的其他治疗药物提供了可能性。

研究设计与样本

  • 前瞻性、单中心、单臂研究,自2018年9月起纳入6例胶质母细胞瘤患者。
  • 在辅助替莫唑胺化疗第1或第2天,于肿瘤切除边缘邻近区域进行MRgFUS血脑屏障破坏,相同靶点共6个周期。
  • 每次声波照射试验后立即行T2*加权/GRE MRI,所有声波照射 session 完成后行综合MRI;每次计划BBBD前2天进行影像学、实验室和临床评估。

主要发现

  • 6例患者共接受145次BBBD试验,涉及脑内不同位置。
  • T1加权MRI在131次试验(90.3%)于BBBD部位观察到钆增强点,T2*加权/GRE MRI在93次试验(64.1%)显示类似斑点。
  • 两序列结合时,在134个靶点(92.4%)观察到BBBD,随访MRI显示斑点消失。
  • 6个周期内无BBBD相关影像学改变和临床不良事件。

局限性

  • 原文指出需要更长的随访期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glioblastoma (GBM) remains fatal due to the blood-brain barrier (BBB), which interferes with the delivery of chemotherapeutic agents. The purpose of this study was to evaluate the safety and feasibility of repeated disruption of the BBB (BBBD) with MR-guided focused ultrasound (MRgFUS) in patients with GBM during standard adjuvant temozolomide (TMZ) chemotherapy. METHODS: This study was a prospective, single-center, single-arm study. BBBD with MRgFUS was performed adjacent to the tumor resection margin on the 1st or 2nd day of the adjuvant TMZ chemotherapy at the same targets for 6 cycles. T2*-weighted/gradient echo (GRE) MRI was performed immediately after every sonication trial, and comprehensive MRI was performed at the completion of all sonication sessions. Radiological, laboratory, and clinical evaluations were performed 2 days before each planned BBBD. RESULTS: From September 2018, 6 patients underwent 145 BBBD trials at various locations in the brain. The authors observed gadolinium-enhancing spots at the site of BBBD on T1-weighted MRI in 131 trials (90.3%) and 93 trials (64.1%) showed similar spots on T2*-weighted/GRE MRI. When the 2 sequences were combined, BBBD was observed in 134 targets (92.4%). The spots disappeared on follow-up MRI. There were no imaging changes related to BBBD and no clinical adverse effects during the 6 cycles. CONCLUSIONS: This study is the first in which repetitive MRgFUS was performed at the same targets with a standard chemotherapy protocol for malignant brain tumor. BBBD with MRgFUS was performed accurately, repeatedly, and safely. Although a longer follow-up period is needed, this study allows for the possibility of other therapeutic agents that previously could not be used due to the BBB.Clinical trial registration no.: NCT03712293 (clinicaltrials.gov).

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Park SH, Kim MJ, Jung HH, et al. Safety and feasibility of multiple blood-brain barrier disruptions for the treatment of glioblastoma in patients undergoing standard adjuvant chemotherapy. J Neurosurg. 2020. PMID: 31899873. doi:10.3171/2019.10.JNS192206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。